its drugs revlimid and thalomid to medicare and state medicaid programs. in addition to listing off-label promotion under the covered conduct, the settlement agreement separately covered alleged "false and misleading" statements celgene made about the drugs, including by concealing or minimizing adverse events. in its july 2017 form 10-q, celgene disclosed that it resolved the matter in full for $315 million, including fees and expenses. the case was brought under the false claims act by beverly brown, a former celgene sales representative. aegerion pharmaceuticals: off-label promotion of juxtapid, september 2017 on september 22, 2017, aegerion pharmaceuticals agreed to pay $28.2 million to resolve allegations that it violated federal marketing rules in promoting its cholesterol medication juxtapid, resulting in the violation of the federal false claims act and state analogues. the settlement resolved allegations that aegerion, promoted juxtapid for off-label uses not approved by the fda, made false and misleading statements to medical practitioners regarding the drug, violated risk-management regulations designed to ensure safe use, and broke anti-kickback laws with charity donations. in addition to civil false claims act liability, aegerion also agreed to a guilty plea involving the same conduct and to pay a criminal fine and forfeiture of $7.2 million. boehringer ingelheim pharmaceuticals inc.: off-label promotion of aggrenox, atrovent, combivent, and micardis, december 2017 in december 2017, boehringer ingelheim pharmaceuticals inc. agreed to pay $13.5 million to settle claims by all 51 state attorneys general (of the 50 states plus the attorney general of the district of columbia) that it engaged in off-label promotion of its drugs aggrenox, atrovent and combivent, and micardis.